Skip to contentO
Outlook Therapeutics, Inc.
O
OTLKOutlook Therapeutics, Inc. Q3 2019 · 10-Q
Revenue$583.85K$583.85K−24.4% vs Q3 2018 Net Income-$4.44M-$4.44MN/M vs Q3 2018 EPS Diluted-$0.20-$0.20N/M vs Q3 2018 Operating Income-$5,644,163N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$10,457,474N/M Margins · derivedOperating margin-966.7%−31.4 pt vs Q3 2018
Net margin-760.6%+331.8 pt vs Q3 2018
ended Jun 30, 2019 · filed Aug 14, 2019 · 45 d after period end